FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 9 2024 16:30:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

12 9 2024 06:55:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming September Conferences

27 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

19 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024

31 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET

24 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress

12 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference

06 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

13 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

13 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate in Upcoming May Conferences

09 5 2024 08:00:01 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

08 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET

06 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

28 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 3 2024 16:30:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

18 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 3 2024 16:30:00 提供 Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

05 3 2024 08:00:00 提供 Nasdaq GlobeNewswire